Skip to main content
. 2022 Mar 7;12:816706. doi: 10.3389/fonc.2022.816706

Figure 2.

Figure 2

Comparison of hypermutated patients. (A) Overall Survival from Diagnosis. (B) Overall Survival from Immunotheraphy Start. (C) Progression-Free Survival from Immunotherapy Start. (D) Overall survival from Chemotherapy Start. (E) Progression-Free Survival from Chemotherapy Start.